Clinical Research Agreement Template for Indonesia

A Clinical Research Agreement is essential when conducting any clinical trial or research study in Indonesia, serving as the legal foundation that governs relationships between pharmaceutical companies, research institutions, and investigators. This comprehensive contract ensures all parties understand their obligations while maintaining compliance with Indonesia's strict regulatory framework for medical research.

When do you need this document?

You need a Clinical Research Agreement whenever conducting clinical trials for pharmaceutical products, medical devices, or therapeutic interventions in Indonesian healthcare facilities. This includes Phase I through Phase IV clinical trials, bioequivalence studies, post-marketing surveillance studies, and investigator-initiated research projects. The agreement is mandatory before enrolling the first patient and must be in place when collaborating with Indonesian hospitals, research centers, or academic institutions. You'll also need this document when establishing partnerships between international sponsors and local Contract Research Organizations (CROs) or Site Management Organizations operating in Indonesia.

Key legal considerations

Your agreement must clearly define each party's responsibilities, including the sponsor's obligation to provide study materials, funding, and regulatory support, while the institution commits to providing qualified investigators and adequate facilities. Patient safety provisions are critical, requiring comprehensive protocols for adverse event reporting, data safety monitoring, and subject protection measures. Financial arrangements must be transparent, covering institutional overhead, investigator fees, and patient compensation structures. Intellectual property clauses should address data ownership, publication rights, and confidentiality requirements. Insurance and indemnification provisions are essential, typically requiring sponsors to maintain comprehensive clinical trial insurance covering potential harm to research subjects.

Legal requirements in Indonesia

Under Indonesian law, your Clinical Research Agreement must comply with Minister of Health Regulation No. 657/MENKES/PER/VIII/2009, which governs clinical trial submissions and conduct. BPOM Regulation No. 21 of 2015 requires specific protocol elements and reporting mechanisms that must be reflected in your agreement. The Health Law No. 36 of 2009 provides the fundamental framework for health research, requiring ethical committee approval and patient consent procedures. Your agreement must specify compliance with Good Clinical Practice (GCP) standards and include provisions for regular monitoring and auditing. Data handling clauses must align with Indonesian privacy regulations and international standards for clinical data management. The agreement should also address regulatory submission requirements, including annual safety reports and study completion notifications to BPOM.